What question did this study set out to answer?

To understand the mutation spectrum in elderly patients with acute myeloid leukemia and its clinical implications.

June 14, 2018HaematologicaOpen Access

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older

View Full Paper

Ask AI

Bookmark

To understand the mutation spectrum in elderly patients with acute myeloid leukemia and its clinical implications.
Analyzed genetic mutations in intensively treated patients aged 75 years or older.
Part of the AMLCG-1999 trial (NCT00266136).
Identified mutations as novel markers for chemorefractory disease.
Found correlations between specific mutations and inferior prognosis.

Randomized trial investigates mutation spectrum and prognosis in elderly patients with acute myeloid leukemia, suggesting new treatment markers.

mutations as a novel marker for chemorefractory disease and inferior prognosis. (AMLCG-1999 trial: clinicaltrials.gov identifier, NCT00266136).

No takes yet. Share an insight, caveat, or question.

Prassek et al. (2018) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial investigates mutation spectrum and prognosis in elderly patients with acute myeloid leukemia, suggesting new treatment markers.

mutations as a novel marker for chemorefractory disease and inferior prognosis. (AMLCG-1999 trial: clinicaltrials.gov identifier, NCT00266136).